Treatment of pediatric epilepsy: Expert opinion, 2005

Journal of Child Neurology

Volumn 20, Issue SUPPL. 1, 2005, Pages

  Wheless, James W ^a   Clarke, Dave F ^a   Carpenter, Daniel ^b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b Univ S Carolina Sch Med Vice P   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CARNITINE; CLOBAZAM; CLONAZEPAM; CORTICOTROPIN; DIAZEPAM; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; FOSPHENYTOIN SODIUM; GABAPENTIN; LAMOTRIGINE; LORAZEPAM; MESUXIMIDE; MIDAZOLAM; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PIRACETAM; PREDNISONE; PREGABALIN; SULTIAME; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ABSENCE; ADJUVANT THERAPY; APLASTIC ANEMIA; BENIGN CHILDHOOD EPILEPSY; BLOOD TOXICITY; BRAIN SURGERY; CHI SQUARE TEST; CLINICAL TRIAL; COMPLEX PARTIAL SEIZURE; CONSENSUS DEVELOPMENT; DISEASE EXACERBATION; DRUG CHOICE; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EPILEPTIC STATE; EVIDENCE BASED MEDICINE; FEBRILE CONVULSION; GRAND MAL SEIZURE; HUMAN; INFANTILE SPASM; KETOGENIC DIET; LENNOX GASTAUT SYNDROME; LIVER TOXICITY; LIVER TRANSPLANTATION; MEDICAL SPECIALIST; MYOCLONUS SEIZURE; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TERATOGENICITY; THERAPY RESISTANCE; TONIC CLONIC SEIZURE; TREATMENT FAILURE; UNITED STATES; VAGUS NERVE STIMULATION;

EID: 32544449791     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/088307380502000101     Document Type: Review

References (186)

1. Goa KL, Ross SR, Chrisp P: Lamotrigine: A review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1993;46:152-176.
2. Anhut H, Ashman P, Feuerstein TJ, et al: Gabapentin as add-on therapy in patients with partial seizures: A double-blind placebo-controlled study. Epilepsia 1994;35:795-801.
3. US Gabapentin Study Group: Gabapentin as add-on therapy in refractory epilepsy: A double-blind, placebo-controlled, parallel-group study. Neurology 1993;43:2292-2298.
4. Gram L: Oxcarbazepine, in Engel J Jr, Pedley TA (eds): Epilepsy: A Comprehensive Textbook. Philadelphia, Lippincott-Raven, 1997, 1541-1566.
5. Kramer LD, Reife RA: Topiramate, in Engel J Jr, Pedley TA (eds): Epilepsy: A Comprehensive Textbook. Philadelphia, Lippincott-Raven, 1997, 1593-1598.
6. Sachdeo RC, Leroy RF, Krauss GL, et al: Tiagabine therapy for complex partial seizures: A dose-frequency study. The Tiagabine Study Group. Arch Neurol 1997;54:595-601.
7. Theodore WH: Felbamate, in Engel J Jr, Pedley TA (eds): Epilepsy: A Comprehensive Textbook. Philadelphia, Lippincott-Raven, 1997, 1509-1514.
8. Cereghino JJ, Biton V, Abou-Khalil B, et al: Levetiracetam for partial seizures: Results of a double-blind randomized clinical trial. Neurology 2000;55:236-242.
9. White HS: Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs. Epilepsia 1999;40 (Suppl 5): S2-S10.
10. Wheless JW, Venkataraman V: New formulations of drugs in epilepsy. Expert Opin Pharmacother 1999;1:49-60.
11. Wilder BJ: Vagal nerve stimulation, in Engel J Jr, Pedley TA (eds): Epilepsy: A Comprehensive Textbook. Philadelphia, Lippincott-Raven, 1997, 1353-1358.
12. Vining EPG: Ketogenic diet, in Engel J Jr, Pedley TA (eds): Epilepsy: A Comprehensive Textbook. Philadelphia, Lippincott-Raven, 1997, 1334-1344.
13. Shmizu H, Kawasaki J, Yuasa S, et al: Use of clobazam for the treatment of refractory complex partial seizures. Seizure 2003;12:282-286.
14. Brodie MJ: Management strategies for localization-related seizures. Epilepsia 2001;42(Suppl 3):27-30.
15. Montenegro MA, Cendes F, Noronha AL, et al: Efficacy of clobazam as add-on therapy in patients with refractory partial epilepsy. Epilepsia 2001;42:539-542.
16. Thiele EA: Managing epilepsy in tuberous sclerosis. J Child Neurol 2004;19:680-686.
17. Wiebe S, Blume WT, Girvin JP, et al: A randomized controlled trial of surgery for temporal lobe epilepsy. N Engl J Med 2001;345:311-318.
18. Wiebe S: Early epilepsy surgery. Curr Neurol Neurosci Rep 2004;4: 315-320.
19. Beydoun A, Uthman BM, Kugler AR, et al: Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology 2005;64:475-480.
20. Arroyo S, Anhut H, Kugler AR, et al: Pregabalin add-on treatment: A randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia 2004; 45:20-27.
21. French JA, Kugler AR, Robbins JL, et al: Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 2003;60:1631-1637.
22. Privitera MD: Evidence-based medicine and antiepileptic drugs. Epilepsia 1999;40(Suppl 5):S47-S56.
23. Williamson PR, Marson AG, Tudur C, et al: Individual patient data meta-analysis of randomized anti-epileptic drug monotherapy trials. J Eval Clin Pract 2000;6:205-214.
24. Hauser WA: The prevalence and incidence of convulsive disorders in children. Epilepsia 1994;35(Suppl 2):S1-S6.
25. Karceski S, Morrell M, Carpenter D: The expert consensus guideline series: Treatment of epilepsy. Epilepsy Behav 2001;2 (Suppl):A1-A50.
26. Karceski S, Morrell MJ, Carpenter D: Treatment of epilepsy in adults: Expert opinion, 2005. Epilepsy Behav 2005;7:S1-S64.
27. Kahn DA, Docherty JP, Carpenter D, Frances A: Consensus methods in practice guideline development: A review and description of a new method. Psychpharmacol Bull 1997;33: 631-639.
28. Dalkey NC: The Delphi Method: An Experimental Study of Group Opinion. Santa Monica, CA. RAND Corporation, 1969, Publication # RM-58888 PR.
29. Woolfe SH: Practice guidelines, a new reality in medicine. Arch Intern Med 1992;152:946-952.
30. Brook RH, Chassin MR, Fink A, et al: A method for the detailed assessment of the appropriateness of medical technologies. Int J Tech Assess Health Care 1986;2:53-63.
31. Frances A, Kahn D, Carpenter D, et al: A new method of developing expert consensus practice guidelines. Am J Manag Care 1998;4:1023-1029.
32. Kahn DA, Carpenter D, Docherty JP, Frances A: The expert consensus guideline series: Treatment of bipolar disorder. J Clin Psychiatry 1996;57(Suppl 12a):1-88.
33. McEvoy JP, Weiden PJ, Smith TE, et al: The expert consensus guideline series: Treatment of schizophrenia. J Clin Psychiatry 1996;57(Suppl 12b):1-58.
34. March JS, Frances A, Carpenter D, Kahn DA: The expert consensus guideline series: Treatment of obsessive-compulsive disorder. J Clin Psychiatry 1997;58(Suppl 4):1-72.
35. Alexopoulos GS, Silver JM, Kahn DA, et al: The expert consensus guideline series: Treatment of agitation in older persons with dementia. Postgrad Med Special Report 1998;April:1-88.
36. McEvoy JP, Scheifler PL, Frances A: The expert consensus guideline series: Treatment of schizophrenia 1999. J Clin Psychiatry 1999;60(Suppl 11):1-80.
37. Foa EB, Davidson JRT, Frances A: The expert consensus guideline series: Treatment of posttraumatic stress disorder. J Clin Psychiatry 1999;60(Suppl 16):1-76.
38. Rush AJ, Frances A: Expert consensus guideline series: Treatment of psychiatric and behavioral problems in mental retardation. Am J Mental Retardation 2000;105:159-228.
39. Sachs GS, Printz DJ, Kahn DA, Carpenter D: The expert consensus guideline series: Medication treatment of bipolar disorder 2000. Postgrad Med Special Report 2000;Apr;1-104.
40. Altshuler LL, Cohen LS, Moline ML, et al: The expert consensus guideline series: Treatment of depression in women 2001. Postgrad Med Special Report 2001;March:1-115.
41. Conners CK, March JS, Frances A, et al: Expert consensus guideline series: Treatment of attention-deficit/hyperactivity disorder. J Atten Disord 2001;4(Suppl 1):S1-S128.
42. Allen MH, Currier GW, Hughes DH, et al: The expert consensus guideline series: Treatment of behavioral emergencies. Postgrad Med Special Report 2001;May:1-88.
43. Alexopoulos GS, Katz IR, Reynolds CF, et al: The expert consensus guideline series: Treatment of depressive disorders in older patients. Postgrad Med Special Report 2001;October: 1-86.
44. Kane JM, Leucht S, Carpenter D, Docherty JP: Expert consensus guideline series: Optimizing pharmacologic treatment of psychotic disorders. J Clin Psychiatry 2003;63(Suppl 12): 5-19.
45. Alexopulos GS, Streim J, Carpenter D, Docherty JP: The expert consensus guideline series: Using antipsychotic agents in older patients. J Clin Psychiatry 2004;65(suppl 2):1-105.
46. Keck PE, Perlis RH, Otto MW, et al: The expert consensus guideline series: Treatment of bipolar disorder 2004. Postgrad Med Special Report 2004;December:1-120.
47. Alexopoulos GS, Jeste DV, Chung H, et al: The expert consensus guideline series: Treatment of dementia and its behavioral disturbances. Postgrad Med Special Report 2005;January: 1-111.
48. Mohanraj R, Brodie MJ: Pharmacological outcomes in newly diagnosed epilepsy. Epilepsy Behav 2005;6:382-387.
49. Bourgeois BF: Chronic management of seizures in the syndromes of idiopathic generalized epilepsy. Epilepsia 2003; 44(Suppl 2):27-32.
50. Biton V, Montouris GD, Ritter F, et al: A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group. Neurology 1999;52:1330-1337.
51. Topiramate (Topamax) package insert, June 2005 (www.orthomcneil.com/products/pi/pdfs/tpamax.pdf#zoom=100).
52. Sankar R, Wheless JW, Dravet C, et al: Treatment of myoclonic epilepsies in infancy and early childhood. Adv Neurol 2005;95:289-298.
53. Guerrini R, Dravet C, Genton P, et al: Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 1998;39: 508-512.
54. Carrazana EJ, Wheeler SD: Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurology 2001;56: 1424-1425.
55. Crespel A, Genton P, Berramdane M, et al: Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies. Neurology 2005;65:762-764.
56. Wheless JW, Bourgeois BF: Choosing antiepileptic drugs for developmentally normal children with specific epilepsy syndromes and behavioral disorders. J Child Neurol 2004;19 (Suppl 1):S39-S48.
57. Wheless JW, Baumgartner J, Ghanbari C: Vagus nerve stimulation and the ketogenic diet. Neurol Clin 2001;19:371-407.
58. Glauser TA, Dulac O: Preliminary efficacy of levetiracetam in children. Epileptic Disord 2003;5(Suppl 1):S45-S50.
59. Glauser TA, Pellock JM: Zonisamide in pediatric epilepsy: Review of the Japanese experience. J Child Neurol 2002;17: 87-96.
60. Pellock JM: Felbamate. Epilepsia 1999;40(Suppl 5):S57-S62.
61. Bryant AE 3rd, Dreifuss FE: Valproic acid hepatic fatalities. III. U.S. experience since 1986. Neurology 1996;46:465-469.
62. Bohan TP, Helton E, McDonald I, et al: Effect of L-carnitine treatment for valproate-induced hepatotoxicity. Neurology 2001;56:1405-1409.
63. Russo MW, Galanko JA, Shrestha R, et al: Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl 2004;10:1018-1023.
64. Kothare SV, Valencia I, Khurana DS, et al: Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy. Epileptic Disord 2004;6:267-270.
65. Wheless JW, Sankar R: Treatment strategies for myoclonic seizures and epilepsy syndromes with myoclonic seizures. Epilepsia 2003;44(Suppl 11):27-37.
66. Bang L, Goa K: Oxcarbazepine: A review of its use in children with epilepsy. Paediatr Drugs 2003;5:557-573.
67. Giroud M, Fayolle H, Gras P, et al: So-called generalized epilepsy in children leading to frontal epilepsy with a frontal syndrome in adulthood: A clinical, EEG and radiological study of 10 cases. Neurol Res 1993;15:299-303.
68. Theodore WH, Porter RJ, Albert P, et al: The secondarily generalized tonic-clonic seizure: A videotape analysis. Neurology 1994;44:1403-1407.
69. Prasad A, Kuzniecky RI, Knowlton RC, et al: Evolving antiepileptic drug treatment in juvenile myoclonic epilepsy. Arch Neurol 2003;60:1100-1105.
70. Guerreiro MM, Vigonius U, Pohlmann H, et al: A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res 1997;27: 205-13.
71. Christe W, Kramer G, Vigonius U, et al: A double-blind controlled clinical trial: Oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res 1997; 26:451-460.
72. Semah F, Picot MC, Derambure P, et al: The choice of antiepileptic drugs in newly diagnosed epilepsy: A national French survey. Epileptic Disord 2004;6:255-265.
73. Aso K, Watanabe K: Limitations in the medical treatment of cryptogenic or symptomatic localization-related epilepsies of childhood onset. Epilepsia 2000;41(Suppl 9):18-20.
74. Semah F, Picot MC, Adam C, et al: Is the underlying cause of epilepsy a major prognostic factor for recurrence? Neurology 1998;51:1256-1262.
75. Dlugos DJ, Sammel MD, Strom BL, Farrar JT: Response to first drug trial predicts outcome in childhood temporal lobe epilepsy. Neurology 2001;57:2259-2264.
76. Spencer SS: When should temporal-lobe epilepsy be treated surgically? Lancet Neurol 2002;1:375-382.
77. Engel J Jr, Wiebe S, French J, et al: Quality Standards Subcommittee of the American Academy of Neurology; American Epilepsy Society; American Association of Neurological Surgeons. Practice parameter: temporal lobe and localized neocortical resections for epilepsy: report of the Quality Standards Subcommittee of the American Academy of Neurology, in association with the American Epilepsy Society and the American Association of Neurological Surgeons. Neurology 2003;60:538-547.
78. Mizrahi EM, Kellaway P, Grossman RG, et al: Anterior temporal lobectomy and medically refractory temporal lobe epilepsy of childhood. Epilepsia 1990;31:302-312.
79. Duchowny M, Levin B, Jayakar P, et al: Temporal lobectomy in early childhood. Epilepsia 1992;33:298-303.
80. Sinclair DB, Aronyk K, Snyder T, et al: Pediatric temporal lobectomy for epilepsy. Pediatr Neurosurg 2003;38:195-205.
81. Erba G, Winston KR, Adler JR, et al: Temporal lobectomy for complex partial seizures that began in childhood. Surg Neurol 1992;38:424-432.
82. Pfizer, Inc.: Prescribing data on file.
83. Scheinfeld N: Impact of phenytoin therapy on the skin and skin disease. Expert Opin Drug Saf 2004;3:655-665.
84. Schmidt D, Elger CE: What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs? Epilepsy Behav 2004;5:627-635.
85. Glauser TA, Nigro M, Sachdeo R, et al: Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology 2000;54: 2237-2244.
86. Barcs G, Walker EB, Elger CE, et al: Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia 2000;41:1597-1607.
87. French JA, Kanner AM, Bautista J, et al: Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004;62:1261-1273.
88. Wheless JW, Clarke DF, in Maria BL (ed): Current Management in Child Neurology, 3rd edition. London, BC Decker, 2005, 503-508.
89. Hodson A. A case for long-term treatment with anticonvulsants. Pharmacotherapy 1985;5:274-277.
90. Lombroso CT. Neonatal seizures: A clinician's overview. Brain Dev 1996;18:128.
91. Tharp BR: Neonatal seizures and syndromes. Epilepsia 2002; 43(Suppl 3):2-10.
92. Gal P, Sharpless MK, Boer HR: Outcome in neonates with seizures: Are chronic anticonvulsants necessary? Ann Neurol 1984;15:610-611 (letter).
93. Bergman I, Painter MJ, Hirsch RP, et al: Outcome in neonates with convulsions treated in an intensive care unit. Ann Neurol 1983;14:642-647.
94. Gal P: Anticonvulsant therapy after neonatal seizures - How long should it be continued? I. A case for early discontinuation of anticonvulsants. Pharmacotherapy 1985;5:268-273.
95. Bittigau P, Sifringer M, Genz K, et al: Antiepileptic drugs and apoptotic neurodegeneration in the developing brain. Proc Natl Acad Sci U S A 2002;99:15089-15094.
96. Bittigau P, Sifringer M, Ikonomidou C: Antiepileptic drugs and apoptosis in the developing brain. Ann N Y Acad Sci 2003; 993:103-114; discussion 123-124.
97. Olney JW, Wozniak DF, Jevtovic-Todorovic V, et al: Drug-induced apoptotic neurodegeneration in the developing brain. Brain Pathol 2002;12:488-498.
98. Painter MJ, Scher MS, Stein AD, et al: Phenobarbital compared with phenytoin for the treatment of neonatal seizures. N Engl J Med 1999;341:485-489.
99. Evans DJ, Levene MI: Anticonvulsants for preventing mortality and morbidity in full term newborns with perinatal asphyxia. Cochrane Database Syst Rev 2001;(3):CD001240.
100. Booth D, Evans DJ: Anticonvulsants for neonates with seizures. Cochrane Database Syst Rev 2004 Oct 18;(4): CD004218.
101. Castro Conde JR, Hernandez Borges AA, Domenech Martinez E, et al: Midazolam in neonatal seizures with no response to phenobarbital. Neurology 2005;64:876-879.
102. Koh S, Jensen FE: Topiramate blocks perinatal hypoxia-induced seizures in rat pups. Ann Neurol 2001;50:366-372.
103. Zhao Q, Hu Y, Holmes GL: Effect of topiramate on cognitive function and activity level following neonatal seizures. Epilepsy Behav 2005;6:529-536.
104. Mackay MT, Weiss SK, Adams-Webber T, et al: American Academy of Neurology; Child Neurology Society. Practice parameter: Medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society. Neurology 2004;62:1668-1681.
105. Kossoff EH, Pyzik PL, McGrogan JR, et al: Efficacy of the ketogenic diet for infantile spasms. Pediatrics 2002;109: 780-783.
106. Wheless JW: Nonpharmacologic treatment of the catastrophic epilepsies of childhood. Epilepsia 2004;45(Suppl 5):17-22.
107. Chugani HT: Infantile spasms. Curr Opin Neurol 1995;8: 139-144.
108. Chugani HT, Shewmon DA, Shields WD, et al: Surgery for intractable infantile spasms: Neuroimaging perspectives. Epilepsia 1993;34:764-771.
109. Mackay M, Weiss S, Snead OC 3rd: Treatment of infantile spasms: An evidence-based approach. Int Rev Neurobiol 2002;49:157-184.
110. Curatolo P, Verdecchia M, Bombardieri R: Vigabatrin for tuberous sclerosis complex. Brain Dev 2001;23:649-653.
111. Hancock E, Osborne J, Milner P: Treatment of infantile spasms. Cochrane Database Syst Rev 2003;(3):CD001770.
112. Fejerman N, Cersosimo R, Caraballo R, et al: Vigabatrin as a first-choice drug in the treatment of West syndrome. Child Neurol 2000;15:161-165.
113. Glauser TA, Clark PO, Strawsburg R: A pilot study of topiramate in the treatment of infantile spasms. Epilepsia 1998; 39:1324-1328.
114. Thijs J, Verhelst H, Van Coster R: Retrospective study of topiramate in a paediatric population with intractable epilepsy showing promising effects in the West syndrome patients. Acta Neurol Belg 2001;101:171-176.
115. Suzuki Y: Zonisamide in West syndrome. Brain Dev 2001;23: 658-661.
116. Yanagaki S, Oguni H, Yoshii K, et al: Zonisamide for West syndrome: A comparison of clinical responses among different titration rate. Brain Dev 2005;27:286-290.
117. Scottish Intercollegiate Guidelines Network: Diagnosis and management of epilepsies in children and young people: A national clinical guideline. Edinburgh, Scottish Intercollegiate Guidelines Network, March 2005 (Copies available at http://www.sign.ac.uk/pdf/sign81.pdf).
118. Frost M, Gates J, Helmers SL, et al: Vagus nerve stimulation in children with refractory seizures associated with Lennox-Gastaut syndrome. Epilepsia 2001;42:1148-1152.
119. Hosain S, Nikalov B, Harden C, et al: Vagus nerve stimulation treatment for Lennox-Gastaut syndrome. J Child Neurol 2000;15:509-512.
120. Karceski S: Vagus nerve stimulation and Lennox-Gastaut syndrome: A review of the literature and data from the VNS patient registry. CNS Spectr 2001;6:766-770.
121. Trevathan E: Infantile spasms and Lennox-Gastaut syndrome. J Child Neurol 2002;17(Suppl 2):2S9-2S22.
122. Covanis A, Gupta AK, Jeavons PM: Sodium valproate: Monotherapy and polytherapy. Epilepsia 1982;23:693-720.
123. Schmidt D, Bourgeois B: A risk-benefit assessment of therapies for Lennox-Gastaut syndrome. Drug Saf 2000;22: 467-477.
124. The Felbamate Study Group in Lennox-Gastaut Syndrome: Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). N Engl J Med 1993;328:29-33.
125. Dodson WE: Felbamate in the treatment of Lennox-Gastaut syndrome: Results of a 12-month open-label study following a randomized clinical trial. Epilepsia 1993;34(Suppl 7): S18-S24.
126. Motte J, Trevathan E, Arvidsson JF, et al: Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. N Engl J Med 1997;337:1807-1812.
127. Sachdeo RC, Glauser TA, Ritter F, et al: A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology 1999;52:1882-1887.
128. Thomson PDR: Physicians' Desk Reference, 59th Edition. Montvale, NJ, Thomson PDR, 2005.
129. Hancock E, Cross H: Treatment of Lennox-Gastaut syndrome. Cochrane Database Syst Rev 2003;(3):CD003277.
130. Pellock JM: Felbamate in epilepsy therapy: Evaluating the risks. Drug Saf 1999;21:225-239.
131. French J, Smith M, Faught E, Brown L: Practice advisory: The use of felbamate in the treatment of patients with intractable epilepsy: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 1999;52:1540-1555.
132. De Los Reyes EC, Sharp GB, Williams JP, Hale SE: Levetiracetam in the treatment of Lennox-Gastaut syndrome. Pediatr Neurol 2004;30:254-256.
133. Shinnar S, Glauser TA: Febrile seizures. J Child Neurol 2002;17(Suppl 1):S44-S52.
134. Baumann RJ: Technical report: Treatment of the child with simple febrile seizures. Pediatrics 1999;103:e86 (http://pediatrics.aappublications.org/cgi/content/full/103/6/e86)
135. American Academy of Pediatrics, Committee on Quality Improvement, Subcommittee on Febrile Seizures: Practice parameter: Long-term treatment of the child with simple febrile seizures. Pediatrics 1999;103(6 Pt 1):1307-1309.
136. Morris GL: Gabapentin. Epilepsia 1999;40(Suppl 5):S63-S70.
137. Bast T, Volp A, Wolf C, Rating D, et al: The influence of sulthiame on EEG in children with benign childhood epilepsy with centrotemporal spikes (BECTS). Epilepsia 2003;44:215-220.
138. Rating D, Wolf C, Bast T: Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: A 6-month randomized, double-blind, placebo-controlled study. Sulthiame Study Group. Epilepsia 2000; 41:1284-1288.
139. Rating D: Treatment in typical and atypical rolandic epilepsy. Epileptic Disord 2000;2(Suppl 1):S69-S72.
140. Corda D, Gelisse P, Genton P, et al: Incidence of drug-induced aggravation in benign epilepsy with centrotemporal spikes. Epilepsia 2001;42:754-759.
141. Posner EB, Mohamed K, Marson AG: Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database Syst Rev 2003;(3):CD003032.
142. National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), sponsor: Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study (expected enrollment: 439, study start: July 2004; for more information, see (www.clinicaltrials.gov/ct/gui/show/NCT00088452).
143. Wilfong A, Schultz R: Zonisamide for absence seizures. Epilepsy Res 2005;64:31-34.
144. Cross JH: Topiramate monotherapy for childhood absence seizures: An open label pilot study. Seizure 2002;11:406-410.
145. French JA, Kanner AM, Bautista J, et al: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004;62:1252-1260.
146. Alsdorf R, Wyszynski DF: Teratogenicity of sodium valproate. Expert Opin Drug Saf 2005;4:345-353.
147. Artama M, Auvinen A, Raudaskoski T, et al: Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology 2005;64:1874-1878.
148. Samren EB, van Duijn CM, Koch S, et al: Maternal use of antiepileptic drugs and the risk of major congenital malformations: A joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 1997;38: 981-990.
149. Wyszynski DF, Nambisan M, Surve T, et al: Antiepileptic Drug Pregnancy Registry: Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005;64:961-965.
150. Vinten J, Adab N, Kini U, et al: Liverpool and Manchester Neurodevelopment Study Group. Neuropsychological effects of exposure to anticonvulsant medication in utero. Neurology 2005;64:949-954.
151. Eriksson K, Viinikainen K, Monkkonen A, et al: Children exposed to valproate in utero: Population based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Res 2005;65:189-200.
152. Adab N, Kini U, Vinten J, et al: The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2004;75:1575-1583.
153. Penry JK, Dean JC, Riela AR: Juvenile myoclonic epilepsy: Long-term response to therapy. Epilepsia 1989;30(Suppl 4):S19-S23; discussion S24-S27.
154. Sullivan JE, Dlugos DJ: Idiopathic generalized epilepsy. Curr Treat Options Neurol 2004;6:231-242.
155. Asconape J, Penry JK: Some clinical and EEG aspects of benign juvenile myoclonic epilepsy. Epilepsia 1984;25: 108-114.
156. Delgado-Escueta AV, Enrile-Bacsal F: Juvenile myoclonic epilepsy of Janz. Neurology 1984;34:285-294.
157. Nicolson A, Appleton RE, Chadwick DW, Smith DF: The relationship between treatment with valproate, lamotrigine, and topiramate and the prognosis of the idiopathic generalised epilepsies. J Neurol Neurosurg Psychiatry 2004;75:75-79.
158. Janz D: Juvenile myoclonic epilepsy: Epilepsy with impulsive petit mal. Cleve Clin J Med 1989;56(Suppl Pt 1):S23-S33; discussion S40-S42.
159. Grunewald RA, Panayiotopoulos CP: Juvenile myoclonic epilepsy: A review. Arch Neurol 1993;50:594-598.
160. Wheless JW, Neto W, Wang S, et al: Topiramate, carbamazepine, and valproate monotherapy: Double-blind comparison in children with newly diagnosed epilepsy. J Child Neurol 2004;19:135-141.
161. Mitchell WG, Chavez JM: Carbamazepine versus phenobarbital for partial onset seizures in children. Epilepsia 1987;28: 56-60.
162. Verity CM, Hosking G, Easter DJ: A multicentre comparative trial of sodium valproate and carbamazepine in paediatric epilepsy. The Paediatric EPITEG Collaborative Group. Dev Med Child Neurol 1995;37:97-108.
163. de Silva M, MacArdle B, McGowan M, et al: Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet 1996;347:709-13.
164. Canadian Study Group for Childhood Epilepsy: Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Epilepsia 1998 ;39:952-9.
165. Zamponi N, Cardinali C: Open comparative long-term study of vigabatrin vs carbamazepine in newly diagnosed partial seizures in children. Arch Neurol 1999;56:605-607.
166. Lowenstein DH, Alldredge BK: Status epilepticus. N Engl J Med 1998;338:970-976.
167. Treiman DM, Meyers PD, Walton NY, et al: A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med 1998;339:792-798.
168. Appleton R, Martland T, Phillips B: Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children. Cochrane Database Syst Rev 2002;(4): CD001905.
169. Wheless JW: Pediatric use of intravenous and intramuscular phenytoin: Lessons learned. J Child Neurol 1998;13(Suppl 1):S11-S14; discussion S30-S32.
170. Wheless JW: Acute management of seizures in the syndromes of idiopathic generalized epilepsies. Epilepsia 2003;44(Suppl 2):22-26.
171. Yu KT, Mills S, Thompson N, Cunanan C: Safety and efficacy of intravenous valproate in pediatric status epilepticus and acute repetitive seizures. Epilepsia 2003;44:724-726.
172. Wheless JW, Venkataraman V: Safety of high intravenous valproate loading dose in epilepsy patients. J Epilepsy 1998;11: 319-324
173. Venkataraman V, Wheless JW: Safety of rapid intravenous infusion of valproate loading doses in epilepsy patients. Epilepsy Res 1999;35:147-153.
174. Wheless JW, Vazquez BR, Kanner AM, et al: Rapid infusion with valproate sodium is well tolerated in patients with epilepsy. Neurology 2004;63:1507-1508.
175. Camfield PR, Camfield CS: Antiepileptic drug therapy: When is epilepsy truly intractable? Epilepsia 1996;37(Suppl 1):S60-S65.
176. Camfield PR, Camfield CS, Gordon K, Dooley JM: If a first antiepileptic drug fails to control a child's epilepsy, what are the chances of success with the next drug? J Pediatr 1997; 131:821-824.
177. Wirrell E, Camfield C, Camfield P, Dooley J: Prognostic significance of failure of the initial antiepileptic drug in children with absence epilepsy. Epilepsia 2001;42:760-763.
178. Kwan P, Brodie MJ: Early identification of refractory epilepsy. N Engl J Med 2000;342:314-319.
179. Brodie MJ, Kwan P: Staged approach to epilepsy management. Neurology 2002;58(8 Suppl 5):S2-S8.
180. Kwan P, Brodie MJ: Drug treatment of epilepsy: When does it fail and how to optimize its use? CNS Spectr 2004;9:110-119.
181. Brodie MJ: Medical therapy of epilepsy: When to initiate treatment and when to combine? J Neurol 2005;252:125-130.
182. Renfroe JB, Wheless JW: Earlier use of adjunctive vagus nerve stimulation therapy for refractory epilepsy. Neurology 2002;59(6 Suppl 4):S26-S30.
183. Fisher RS, Handforth A: Reassessment: Vagus nerve stimulation for epilepsy: A report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 1999;53:666-669.
184. Commission on the Classification and Terminology of the International League Against Epilepsy: Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30:389-399.
185. Glauser TA. Purpose and development of the guidelines. Presented as part of a session titled Impact of ILAE Guidelines: Initial monotherapy treatment of epileptic seizures and syndromes with antiepileptic drugs, at the 26th International Epilepsy Congress, Paris, France, September 1, 2005. Abstract in Epilepsia; 2005;46 (suppl 6):47-48.
186. National Institute for Clinical Excellence (NICE): Technology Appraisal Guidance 79, Newer Drugs for Epilepsy in Children (www.nice.org/uk/TA 079 guidance) and Clinical Guideline 20, The Epilepsies: The Diagnosis and Management of the Epilepsies in Adults and Children in Primary and Secondary Care, October 2004 (www.nice.org/uk/CG020NICE guideline).